Q-omics provides the consensus-scored MIR2117HG profile across patient tissues and cancer cell-line models. MIR2117HG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR2117HG is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MIR2117HG RNA expression shows 13,008 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, THCA, and THYM as cancer lineages where MIR2117HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2117HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2117HG survival associations across molecular data types. MIR2117HG RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2117HG RNA expression–survival associations across cancer types. High MIR2117HG expression shows unfavorable associations in KIRC, KIRP, THCA, ACC and COAD, but favorable associations in UCEC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR2117HG RNA expression.
This table summarizes MIR2117HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2117HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2117HG shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUSC, LUAD and BLCA. The THCA box plot shows higher MIR2117HG RNA expression in normal versus tumor tissue (log2 FC = −1.247, t-test p < 0.001).
This table shows molecular features associated with MIR2117HG in patient tissues and cancer cell lines. In patient samples, MIR2117HG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
